Atuk Tankut
Department of Gender, Women and Sexuality Studies, University of Minnesota Twin Cities, St. Paul, MN, United States.
Front Sociol. 2020 Aug 12;5:53. doi: 10.3389/fsoc.2020.00053. eCollection 2020.
This paper unveils the pathologies that are produced and sustained by the pharmaceutical industry, specifically by Gilead Sciences, Inc. Broadly defined, pathopolitics is the politics of treating and/or reproducing pathologies. This paper examines pathopolitics in the context of PrEP, or , an antiretroviral medicine that prevents HIV transmission. Although Gilead promises to prevent a pathology through PrEP, it reproduces social and biological pathologies by exposing certain people to higher risks of infections and diseases, thus epitomizing the operating logic of the pharmaceutical industry: that life is protected only insofar as it offers surplus economic and social value. This essay raises three fundamental sets of questions: (1) What are the techniques and mechanics of pathopolitics? (2) How does the pharmaceutical industry produce and exploit surplus value? (3) What is the nature of the relationship between the pharmaceutical citizenship and pathopolitics?
本文揭示了制药行业，特别是吉利德科学公司所制造并维持的病理状况。宽泛地定义，病理政治学是关于治疗和/或复制病理状况的政治学。本文在暴露前预防（PrEP），即一种预防艾滋病毒传播的抗逆转录病毒药物的背景下审视病理政治学。尽管吉利德承诺通过暴露前预防来预防一种病理状况，但它却通过使某些人面临更高的感染和疾病风险，从而复制了社会和生物病理状况，由此体现了制药行业的运作逻辑：即生命只有在能提供额外经济和社会价值时才会得到保护。本文提出了三组基本问题：（1）病理政治学的技术和机制是什么？（2）制药行业如何产生和利用剩余价值？（3）制药公民身份与病理政治学之间的关系本质是什么？
